Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-07-24

Omeros (OMER)

Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$4,178,008
Gregory Demopulos total, FY2025
70th
CEO pay percentile vs peers
21.8:1
CEO-to-median pay ratio
78.05%
Say-on-pay support, latest vote
Companies that benchmark against OMER
2 companies name OMER as a compensation peer

Each company listed discloses OMER in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named OMER in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Gregory Demopulos$972,525$972,525$0$2,207,974$0$0$24,984$4,178,008
President, Chief Executive Officer and Chairman of the Board
Peter Cancelmo489,480171,3180255,257004,647920,702
Vice President, General Counsel and Secretary
David Borges325,600113,7500242,494004,430686,274
Vice President, Finance, Chief Accounting Officer and Treasurer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY20242025
Gregory Demopulos$4,178,008$3,764,151$7,689,843+413,857
Peter Cancelmo920,702906,894852,633+13,808
David Borges686,274627,907+58,367

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Thomas J. CableDirector2026-05-22A7,500$11$81,300CommonForm 4 ↗
Thomas J. CableDirector2026-05-22D7,5001287,039CommonForm 4 ↗
Thomas J. CableDirector2026-05-22D7,50000Derivative, Class A CommonForm 4 ↗
Thomas J. CableDirector2026-06-18A15,00000Derivative, Class A CommonForm 4 ↗
Thomas F. BumolDirector2026-06-18A15,00000Derivative, Class A CommonForm 4 ↗
Leroy E. Hood MD PhDDirector2026-06-18A15,00000Derivative, Class A CommonForm 4 ↗
Gregory DemopulosDirector2026-06-18A15,00000Derivative, Class A CommonForm 4 ↗
Diana T. PerkinsonDirector2026-06-18A15,00000Derivative, Class A CommonForm 4 ↗
Rajiv ShahDirector2026-06-18A15,00000Derivative, Class A CommonForm 4 ↗
Arnold C. HanishDirector2026-06-18A15,00000Derivative, Class A CommonForm 4 ↗
Peter CancelmoVP, General Counsel2026-07-22A105,00000Derivative, Class A CommonForm 4 ↗
David BorgesVP, Finance & CAO2026-07-22A105,00000Derivative, Class A CommonForm 4 ↗
Gregory DemopulosDirector2026-07-22A1,000,00000Derivative, Class A CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Gregory DemopulosOPTION2025-06-30865,000$2,207,974
Peter CancelmoOPTION2025-06-30100,000255,257
David BorgesOPTION2025-06-3095,000242,494
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Gregory Demopulos$0$0$2,207,9740.0%
Peter Cancelmo00255,2570.0%
David Borges00242,4940.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Gregory DemopulosOption54,1673.93
David BorgesOption8,3332.94
David BorgesOption55,4173.06
Peter CancelmoOption6,6673.93
David BorgesOption79,1673.2
David BorgesOption1,6673.93
Gregory DemopulosOption720,8333.2
Gregory DemopulosOption422,9173.06
Peter CancelmoOption33,3332.94
Peter CancelmoOption58,3333.06
Peter CancelmoOption83,3333.2
Gregory DemopulosOption238,3332.94
05

Incentive-plan design — the Compensation Discussion & Analysis

We orient our executive compensation program to: Provide total compensation opportunities that enable us to recruit and retain executives with the experience and skills needed to manage the growth of our company and lead us to the next stage of development. Establish a clear alignment between the interests of our executives and the interests of our shareholders. Reinforce a culture of ownership, excellence and urgency. Create a direct and meaningful link between company business results, individual performance and compensation.

CEO STI target (% of salary)100%
CEO LTI target (% of salary)
Independent consultantCompensia
Clawback policyTrue
Anti-hedgingTrue
Anti-pledgingTrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-06-1824,384,4456,856,592507,82178.05%Passed
20252025-06-2715,086,3681,856,643615,51189.04%Passed
20242024-06-0615,849,5456,977,695468,29469.43%Passed
20232023-06-2320,792,2712,594,301405,17788.91%Passed
20202020-06-0525,967,4691,316,736603,55395.17%Passed
20172017-06-2216,084,4783,980,923364,11180.16%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-06-1878.05%a
20252025-06-2789.04%b
20242024-06-0669.43%c

a. Approved under the standard stated in the filing — “Accordingly, abstentions will not affect the determination of the directors who have received the highest number of affirmative votes or whether the votes cast in favor of Proposals 2, 3 or 4 exceed those cast against each such proposal.”.

b. Approved under the standard stated in the filing — “Accordingly, abstentions will not affect the determination of the directors who have received the highest number of affirmative votes or whether the votes cast in favor of Proposals 2 or 3 exceed those cast against each such proposal.”.

c. Approved under the standard stated in the filing — “Accordingly, abstentions will not affect the determination of the directors who have received the highest number of affirmative votes or whether the votes cast in favor of Proposals 2 or 3 exceed those cast against each such proposal.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)21.8 : 1
CEO total compensation$4,178,008
Median employee compensation$191,656
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Thomas J. CableIndependent · Lead Independent Director · Audit · Compensation (Chair) · Nominating and Governance (Chair)$110,000$0$41,060$0$151,060
Rajiv Shah, M.DIndependent · Audit · Compensation72,500041,0600113,560
Arnold C. HanishIndependent · Audit (Chair)70,000041,0600111,060
Leroy E. Hood, M.D., Ph.DIndependent · Compensation · Nominating and Governance · Scientific67,500041,0600108,560
Diana T. Perkinson, M.DIndependent · Nominating and Governance · Scientific60,000041,0600101,060
Thomas F. Bumol, Ph.DIndependent · Scientific (Chair)60,000041,0600101,060
Peter A. Demopulos, M.DNot independent · Scientific55,000041,060096,060
Gregory A. Demopulos, M.DEmployee director · Board Chair00000
09

Board fee structure and ownership guideline

Annual cash retainer$50,000
Annual equity retainer$41,060
Per board meeting fee
Committee chair fees (audit / comp / nom-gov)20,000 / 20,000 / 20,000
Stock ownership guideline
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$495,000
Equity awards (grant-date value)$0
All other compensation$0
Total cost of the board$495,000

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies Omeros names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Omeros.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Pacira BioSciences, Inc.2025Frank Lee$935,308$9,215,500$0$738,810$11,636,917
2Arcus Biosciences, Inc.2025Terry Rosen775,0002,199,4506,008,860658,7509,656,813
3Agios Pharmaceuticals, Inc.2025Brian Goff846,8641,291,6802,627,252592,8045,370,389
4Omeros2025Gregory Demopulos972,52502,207,97404,178,008
5Vanda Pharmaceuticals, Inc.2025Mihael Polymeropoulos965,6552,007,0000834,3263,851,468
6Esperion Therapeutics, Inc.2025Sheldon Koenig770,8331,260,000847,929639,3753,535,512
7Aclaris Therapeutics, Inc.2025Neal Walker615,000828,4261,581,615350,5503,375,591
8Enanta Pharmaceuticals, Inc.2025Jay Luly803,300128,5501,223,975591,6652,769,548
9Karyopharm Therapeutics2025Richard Paulson770,000838,996241,544350,3502,320,902
10Ironwood Pharmaceuticals, Inc.2025Thomas McCourt867,568411,6960650,6761,948,390
11Collegium Pharmaceutical,2025Vikram Karnani875,00000835,4061,715,846
12Mersana Therapeutics, Inc.2024Michael Huber632,500133,635518,044322,5751,613,754

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Omeros100%Options 100not disclosedCompensia
Aclaris Therapeutics, Inc.not disclosednot disclosednot disclosedPearl Meyer
Agios Pharmaceuticals, Inc.100%Options 40 · PSU 40 · RSU 20NoAon
Arcus Biosciences, Inc.100%Options 67 · RSU 33not disclosedRadford
Collegium Pharmaceutical,127.3%RSU 70 · PSU 30Yes — relative ranking of the total shareholder return (TSR) of the Company's common stock in 2025, 2026, 2027 and the cumulative three-year performance period (2025-2027) return relative to the TSR of peer companies within the S&P Pharmaceutical Select Industry IndexAlpine Rewards, LLC
Enanta Pharmaceuticals, Inc.not disclosedOptions 80 · PSU 10 · MSU 10NoAlpine Rewards LLC
Esperion Therapeutics, Inc.110%not disclosednot disclosednot disclosed
Ironwood Pharmaceuticals, Inc.100%PSU 50 · RSU 50Yes — relative total stockholder return (rTSR)Alpine Rewards LLC
Karyopharm Therapeutics90%not disclosedYes — Relative TSRAlpine Rewards, LLC (through September 2025); Willis Towers Watson (beginning August 2025)
Mersana Therapeutics, Inc.85%Options 75 · RSU 25not disclosedPearl Meyer & Partners, LLC
Pacira BioSciences, Inc.90%RSU 100NoAon (Aon plc, Human Capital Solutions practice)
Vanda Pharmaceuticals, Inc.108%not disclosedYes — Relative TSRWillis Towers Watson

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Gregory DemopulosDEF 14A2026-04-300001552781-26-000281Section “Summary Compensation Table”. As printed: 4,178,008. Filing ↗machine: t160 · r1 · c6 · span 462502–462511
2Section 01, Peter CancelmoDEF 14A2026-04-300001552781-26-000281Section “Summary Compensation Table”. As printed: 920,702. Filing ↗machine: t160 · r6 · c6 · span 472235–472242
3Section 01, David BorgesDEF 14A2026-04-300001552781-26-000281Section “Summary Compensation Table”. As printed: 686,274. Filing ↗machine: t160 · r4 · c6 · span 468201–468208
4Section 03, Gregory Demopulos OPTIONDEF 14A2026-04-300001552781-26-000281Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t167 · r1 · c5 · span 488840–488849
5Section 03, Peter Cancelmo OPTIONDEF 14A2026-04-300001552781-26-000281Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t167 · r3 · c5 · span 491713–491720
6Section 03, David Borges OPTIONDEF 14A2026-04-300001552781-26-000281Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t167 · r2 · c5 · span 490264–490271
7Section 07, pay ratioDEF 14A2026-04-300001552781-26-000281Section “CEO Pay Ratio”. As printed: 21.8 : 1. Filing ↗
8Section 08, Thomas J. CableDEF 14A2026-04-300001552781-26-000281Section “Director Compensation”. As printed: 151,060. Filing ↗machine: t111 · r2 · c3 · span 328349–328356
9Section 08, Rajiv Shah, M.DDEF 14A2026-04-300001552781-26-000281Section “Director Compensation”. As printed: 113,560. Filing ↗machine: t111 · r7 · c3 · span 333326–333333
10Section 08, Arnold C. HanishDEF 14A2026-04-300001552781-26-000281Section “Director Compensation”. As printed: 111,060. Filing ↗machine: t111 · r4 · c3 · span 330332–330339
11Section 08, Leroy E. Hood, M.D., Ph.DDEF 14A2026-04-300001552781-26-000281Section “Director Compensation”. As printed: 108,560. Filing ↗machine: t111 · r5 · c3 · span 331330–331337
12Section 08, Diana T. Perkinson, M.DDEF 14A2026-04-300001552781-26-000281Section “Director Compensation”. As printed: 101,060. Filing ↗machine: t111 · r6 · c3 · span 332326–332333
13Section 08, Thomas F. Bumol, Ph.DDEF 14A2026-04-300001552781-26-000281Section “Director Compensation”. As printed: 101,060. Filing ↗machine: t111 · r1 · c3 · span 327361–327368
14Section 08, Peter A. Demopulos, M.DDEF 14A2026-04-300001552781-26-000281Section “Director Compensation”. As printed: 96,060. Filing ↗machine: t111 · r3 · c3 · span 329345–329351
15Section 08, Gregory A. Demopulos, M.DDEF 14A2026-04-300001552781-26-000281Section “Director Compensation”. As printed: 0. Filing ↗
16Section 02, Thomas J. Cable 2026-05-22Form 42026-05-270001437749-26-018625Insider equity transaction reported since the proxy statement. Filing ↗
17Section 02, Thomas J. Cable 2026-05-22Form 42026-05-270001437749-26-018625Insider equity transaction reported since the proxy statement. Filing ↗
18Section 02, Thomas J. Cable 2026-05-22Form 42026-05-270001437749-26-018625Insider equity transaction reported since the proxy statement. Filing ↗
19Section 02, Thomas J. Cable 2026-06-18Form 42026-06-220001437749-26-021235Insider equity transaction reported since the proxy statement. Filing ↗
20Section 02, Thomas F. Bumol 2026-06-18Form 42026-06-220001437749-26-021234Insider equity transaction reported since the proxy statement. Filing ↗
21Section 02, Leroy E. Hood MD PhD 2026-06-18Form 42026-06-220001437749-26-021238Insider equity transaction reported since the proxy statement. Filing ↗
22Section 02, Gregory Demopulos 2026-06-18Form 42026-06-220001437749-26-021236Insider equity transaction reported since the proxy statement. Filing ↗
23Section 02, Diana T. Perkinson 2026-06-18Form 42026-06-220001437749-26-021239Insider equity transaction reported since the proxy statement. Filing ↗
24Section 02, Rajiv Shah 2026-06-18Form 42026-06-220001437749-26-021240Insider equity transaction reported since the proxy statement. Filing ↗
25Section 02, Arnold C. Hanish 2026-06-18Form 42026-06-220001437749-26-021237Insider equity transaction reported since the proxy statement. Filing ↗
26Section 02, Peter Cancelmo 2026-07-22Form 42026-07-240001437749-26-024441Insider equity transaction reported since the proxy statement. Filing ↗
27Section 02, David Borges 2026-07-22Form 42026-07-240001437749-26-024439Insider equity transaction reported since the proxy statement. Filing ↗
28Section 02, Gregory Demopulos 2026-07-22Form 42026-07-240001437749-26-024443Insider equity transaction reported since the proxy statement. Filing ↗
29Section 06, 2026 voteForm 8-K2026-06-250001437749-26-021617Item 5.07 · say-on-pay result. As reported: 78.05% (votes for as printed: 24,384,445). Filing ↗
30Section 06, 2025 voteForm 8-K2025-07-020001437749-25-021959Item 5.07 · say-on-pay result. As reported: 89.04% (votes for as printed: 15,086,368). Filing ↗
31Section 06, 2024 voteForm 8-K2024-06-120001437749-24-020102Item 5.07 · say-on-pay result. As reported: 69.43% (votes for as printed: 15,849,545). Filing ↗
32Section 01 trend, Δ column (computed)ComputedcomputedΔ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
33Section 03b vehicle mix (computed)ComputedcomputedRSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
34Section 09b board cost (computed)ComputedcomputedCash 495,000 + equity 0 + all other 0 = 495,000, summed across the director compensation table rows.machine: formula: Σ = 495,000
35Pacira BioSciences, Inc., Section 10b CEO totalDEF 14A2026-04-280001104659-26-050353CEO total compensation as printed in Pacira BioSciences, Inc.'s own proxy. As printed: 11,636,917. Filing ↗machine: t136 · r1 · c47 · span 2412158–2412168
36Arcus Biosciences, Inc., Section 10b CEO totalDEF 14A2026-04-210001724521-26-000025CEO total compensation as printed in Arcus Biosciences, Inc.'s own proxy. As printed: 9,656,813. Filing ↗machine: r2 · c48 · span 403740–403749
37Agios Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-240001193125-26-177086CEO total compensation as printed in Agios Pharmaceuticals, Inc.'s own proxy. As printed: 5,370,389. Filing ↗machine: r2 · c31 · span 613185–613194
38Omeros (subject), Section 10b CEO totalDEF 14A2026-04-300001552781-26-000281CEO total compensation as printed in Omeros's own proxy. As printed: 4,178,008. Filing ↗machine: t160 · r1 · c6 · span 462502–462511
39Vanda Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-230001628280-26-026893CEO total compensation as printed in Vanda Pharmaceuticals, Inc.'s own proxy. As printed: 3,851,468. Filing ↗machine: span 563696–563705
40Esperion Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-160001628280-26-025499CEO total compensation as printed in Esperion Therapeutics, Inc.'s own proxy. As printed: 3,535,512. Filing ↗machine: span 423838–423847
41Aclaris Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-230001104659-26-047262CEO total compensation as printed in Aclaris Therapeutics, Inc.'s own proxy. As printed: 3,375,591. Filing ↗machine: r2 · c14 · span 317880–317889
42Enanta Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-01-260001193125-26-022558CEO total compensation as printed in Enanta Pharmaceuticals, Inc.'s own proxy. As printed: 2,769,548. Filing ↗machine: r2 · c16 · span 830357–830366
43Karyopharm Therapeutics, Section 10b CEO totalDEF 14A2026-04-130001503802-26-000023CEO total compensation as printed in Karyopharm Therapeutics's own proxy. As printed: 2,320,902. Filing ↗machine: r2 · c29 · span 1192339–1192348
44Ironwood Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-280001104659-26-050325CEO total compensation as printed in Ironwood Pharmaceuticals, Inc.'s own proxy. As printed: 1,948,390. Filing ↗machine: t29 · r1 · c48 · span 584182–584191
45Collegium Pharmaceutical,, Section 10b CEO totalDEF 14A2026-04-070001628280-26-024063CEO total compensation as printed in Collegium Pharmaceutical,'s own proxy. As printed: 1,715,846. Filing ↗machine: r2 · c48 · span 779394–779403
46Mersana Therapeutics, Inc., Section 10b CEO totalDEF 14A2025-04-290001104659-25-040448CEO total compensation as printed in Mersana Therapeutics, Inc.'s own proxy. As printed: 1,613,754. Filing ↗machine: t16 · r1 · c41 · span 608188–608197
47Section 10a, Pacira BioSciences, Inc. reciprocityDEF 14A0001104659-26-050353Pacira BioSciences, Inc.'s most recent proxy was read; its disclosed peer group does not include Omeros. Filing ↗
48Section 10a, Vanda Pharmaceuticals, Inc. reciprocityDEF 14A0001628280-26-026893Vanda Pharmaceuticals, Inc. names Omeros in its own disclosed peer group (read from its most recent proxy). Filing ↗
49Section 10a, Collegium Pharmaceutical, reciprocityDEF 14A0001628280-26-024063Collegium Pharmaceutical,'s most recent proxy was read; its disclosed peer group does not include Omeros. Filing ↗
50Section 10a, Enanta Pharmaceuticals, Inc. reciprocityDEF 14A0001193125-26-022558Enanta Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Omeros. Filing ↗
51Section 10a, Mersana Therapeutics, Inc. reciprocityDEF 14A0001104659-25-040448Mersana Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Omeros. Filing ↗
52Section 10a, Agios Pharmaceuticals, Inc. reciprocityDEF 14A0001193125-26-177086Agios Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Omeros. Filing ↗